The goal of this clinical trial is to discover if an overdose prevention app (UnityPhilly) can encourage citizen responders to respond and prevent opioid overdoses using the UnityPhilly app. The main hypotheses to answer are:
Hypothesis 1: UnityPhilly signal rates relative to EMS calls will increase over time. The primary outcome will be assessed as the total number of overdoses signaled by participants relative to all overdose-related EMS calls, per year.
Hypothesis 2: The number of cases where a nearby UnityPhilly participant successfully reverses an overdose with naloxone will increase over time. The primary outcome will be assessed as the number of successful reversals relative to the total number of responder arrivals, per year.
Participants will be supplied with the UnityPhilly app, training on how to use the app and respond to an opioid overdose using naloxone, and respond to follow up surveys about their experiences.

开始日期2024-10-01

申办/合作机构

Drexel University

[+2]

NCT06045767 / Not yet recruiting临床2期IIT

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

This is a single site, non-randomized trial for the assessment of intravenous (IV) pembrolizumab (also known as MK-3475) combined with pemetrexed/platinum-based chemotherapy in subjects with advanced or metastatic non-squamous non-small lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease and in whom directed therapy is not indicated. Approximately 30 subjects will be enrolled in this trial to examine the clonality and diversity dynamics matched with disease response evaluated by RECIST 1.1.

开始日期2024-06-01

申办/合作机构

Tel Aviv Sourasky Medical Center

[+2]

NCT06030830 / RecruitingN/AIIT

SMaRT Mom - Smartphone Management and Responsive Time for Breastfeeding Mothers - An Intervention Study

In the last decade, infants are born into a social environment in which the smartphone has become an essential part of our lives. Smartphone use draws the mother's attention during mother-infant interactions and thus may affect the infant development as well as maternal self-efficacy. However, the effects of smartphone use reduction among breastfeeding mothers during their interactions with their infants have not been studied yet. In the present study, we propose to evaluate a "SMaRT Mom" intervention that we have developed, to manage and reduce smartphone use during breastfeeding. The purpose of the study is to evaluate the effects of the SMaRT Mom intervention on breastfeeding mothers' biobehavioral mechanisms, self-efficacy and the socioemotional characteristics of their infants. This will extend our knowledge of the peculiarities of early mother-infant interactions in the digital era, when smartphones play a critical role.

开始日期2023-06-06

申办/合作机构

Bar-Ilan University

100 项与 Bar-Ilan University 相关的临床结果

登录后查看更多信息

0 项与 Bar-Ilan University 相关的专利（医药）

登录后查看更多信息

18,636

项与 Bar-Ilan University 相关的文献（医药）

2025-01-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Super-Spectral-Resolution Raman spectroscopy using angle-tuning of a Fabry-Pérot etalon with application to diamond characterization

Article

作者: Nedvedski, Romi ; Tischler, Hadass ; Tischler, Yaakov R. ; Tischler, Yaakov R ; Mandelbaum, Yaakov ; Amiel, Yishai

Raman spectroscopy is an extremely powerful laser-based method for characterizing materials based on their unique inelastic scattering spectrum. Ultimately, the power of the technique is limited by the resolution of the spectrometer. Here we introduce a new method for achieving Super-Spectral-Resolution Raman Spectroscopy (SSR-RS), by angle-tuning a Fabry-Pérot (F-P) etalon filter that we incorporated in a micro-Raman setup. A monolithically coated F-P etalon structure, only 1.686 mm in thickness, was mounted onto an angle-tunable motorized stage, and Raman spectra were automatically acquired for many different angles of the etalon. Using a low-resolution grating of 150 g/mm by itself, without the F-P etalon, we obtained a best-case regular Raman spectral linewidth of 44 cm^-1 for the characteristic Raman peak from a diamond sample. When we applied the SSR-RS technique to diamond, we obtained a super-spectral resolution peak that was 27x narrower, namely 1.63 cm^-1, and a Raman shift of 1331.3 cm^-1. To baseline SSR-RS, we applied the super-spectral-resolution method to extract the linewidth and peak wavelength of the laser excitation itself and obtained a laser linewidth of better than 0.014 cm^-1, with a laser wavelength centered at 531.962 nm, close to the stated wavelength of 532 nm. This extracted laser linewidth is 3300x times narrower compared to its measured linewidth of 46 cm^-1. Thus, our work suggests that SSR-RS can be very generally applied to greatly improve the resolution and precision of Raman instrumentation, and potentially lower the cost of obtaining high-resolution Raman spectroscopic capabilities.

2025-01-01·Methods in molecular biology (Clifton, N.J.)

A Computational Approach for Designing Synthetic Riboswitches for Next-Generation RNA Therapeutics.

Article

作者: Mukherjee, Sunanda Biswas ; Mukherjee, Sumit ; Barash, Danny

Riboswitches are naturally occurring regulatory segments of RNA molecules that modulate gene expression in response to specific ligand binding. They serve as a molecular 'switch' that controls the RNA's structure and function, typically influencing the synthesis of proteins. Riboswitches are unique because they directly interact with metabolites without the need for proteins, making them attractive tools in synthetic biology and RNA-based therapeutics. In synthetic biology, riboswitches are harnessed to create biosensors and genetic circuits. Their ability to respond to specific molecular signals allows for the design of precise control mechanisms in genetic engineering. This specificity is particularly useful in therapeutic applications, where riboswitches can be synthetically designed to respond to disease-specific metabolites, thereby enabling targeted drug delivery or gene therapy. Advancements in designing synthetic riboswitches for RNA-based therapeutics hinge on sophisticated computational techniques, which are described in this chapter. The chapter concludes by underscoring the potential of computational strategies in revolutionizing the design and application of synthetic riboswitches, paving the way for advanced RNA-based therapeutic solutions.

2024-12-31·European journal of psychotraumatology

Does disconfirmatory evidence shape safety-and danger-related beliefs of trauma-exposed individuals?

Article

作者: Neria, Yuval ; Kube, Tobias ; Lazarov, Amit ; Michael, Tanja ; Haim-Nachum, Shilat ; Rozenkrantz, Liron ; Sopp, M Roxanne ; Levy-Gigi, Einat

Recent accounts of predictive processing in posttraumatic stress disorder (PTSD) suggest that trauma-exposed individuals struggle to update trauma-related hypotheses predicting danger, which may be involved in the etiology and maintenance of this disorder. Initial research supports this account, documenting an association between trauma-exposure, impaired expectation updating, and PTSD symptoms. Yet, no study to date has examined biased belief updating in PTSD using a scenario-based approach.Objective: Here, we examined the predictive processing account among trauma-exposed and non-trauma-exposed individuals using a modified Trauma-Related version of the Bias Against Disconfirmatory Evidence task.Method: The task presents both danger-and safety-related scenarios highly relevant for trauma-exposed individuals. For each scenario, participants viewed several explanations and rated their plausibility. Their ability to update their initial interpretation following new-contradictory information was assessed.Results: Preregistered analyses did not reveal any significant findings. Based on indications that our sample may not have been sufficiently powered, we conducted exploratory analyses in an extended sample of participants. These analyses yielded a significant association between reduced belief updating and PTSD symptoms which was evident for disconfirming both safety and danger scenarios. However, the effect sizes we found were in the small-to-medium range.Conclusion: Although preliminary, our current findings support initial evidence that individuals with higher PTSD symptoms show a higher resistance to update their beliefs upon new disconfirmatory evidence. Our results should be interpreted cautiously in light of the extended sample and the limitations of the current study.

项与 Bar-Ilan University 相关的新闻（医药）

2024-09-04

·GlobeNewswire-Health Care

Nanocarry Therapeutics' Brain Penetrating Nanoplatform Selected by the NCI Nanotechnology Characterization Laboratory for its Preclinical Characterization Program

Program Will Facilitate Filing an IND Application Toward Human Clinical TrialsNESS ZIONA, Israel, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Nanocarry Therapeutics, a pioneering biopharmaceutical company focused on advancing treatments for brain diseases through its innovative AxS nanoparticle platform, announced the selection of its lead product, AxS007, by the U.S. National Cancer Institute’s (NCI’s) Nanotechnology Characterization Laboratory (NCL) for comprehensive preclinical characterization. The NCL is located at the Frederick National Laboratory for Cancer Research, operated for NCI by Leidos Biomedical Research, Inc. Over 400 million people globally suffer from brain diseases that remain insufficiently treated due to the Blood-Brain Barrier (BBB) blocking most therapeutics. Nanocarry's AxS technology utilizes an insulin-based nanoplatform to cross the BBB, enabling the delivery of multiple copies and combinations of antibodies, small molecules, and other therapeutics to the brain, thus targeting various central nervous system disorders. AxS007 specifically targets brain metastases of HER2+ breast cancer, which affects 50% of metastatic breast cancer patients and represents a significant unmet need. The NCL was established to advance the use of nanotechnology in cancer research and accelerate the development of promising nanomedicine-based therapeutics. The NCI partners with the National Institute of Standards and Technology (NIST) and the FDA, offering preclinical testing and services on a competitive acceptance basis, to expedite the transition of nanomedicines from early-stage development to clinical applications. Through this collaboration, the NCL will conduct detailed preclinical evaluations of AxS007. These studies will support the advancement of AxS007 towards filing an Investigational New Drug (IND) application with the FDA and facilitate future clinical development. This partnership will also strengthen collaborations focused on utilizing AxS technology with diverse therapeutic agents to treat various brain diseases. "We are very pleased and honored that AxS007 has been selected for the NCL program, marking a pivotal moment for Nanocarry Therapeutics," said Revital Mandil-Levin, Co- founder and CEO of Nanocarry Therapeutics. "The detailed characterization by the NCL will significantly accelerate the development of AxS007 towards clinical trials. Our lead product addresses breast cancer brain metastases, a severe complication of HER2+ metastatic breast cancer in which current treatments often fail due to the BBB, drastically reducing survival rates. Our mission is to replicate the prominent success of HER2+ therapeutic antibodies and extend it to the brain, aiming to improve outcomes for the 1 in 8 women who will develop breast cancer in their lifetime.” About Nanocarry Therapeutics Nanocarry Therapeutics is a biopharmaceutical company dedicated to transforming brain disease treatment through an advanced insulin-based nano delivery system that crosses the blood-brain barrier. Founded in 2021 and rooted in the nano-bioengineering lab at Bar Ilan University, the company's lead product targets HER2+ breast cancer brain metastases and is now entering IND-enabling studies. The early pipeline also includes neurodegenerative diseases. Nanocarry Therapeutics aims to improve patient outcomes by delivering innovative therapies to previously unreachable areas of the brain. For more information about Nanocarry Therapeutics, visit www.nanocarry.com. Nanocarry contact:Michal Roytman Chief Business Officer Tel: +972-50-8460424michal@nanocarry.com

2024-05-06

·Science Daily

Direct measurement of the interaction between immune cells and cancer cells from a patient's biopsy

Researchers have unveiled a technology that promises to improve cancer treatment decisions based on a patient's biopsy. The pioneering biological research and development measures changes in immune system cells adjacent to cancer cells, providing crucial insights into the patient's immune response and potentially enhancing the effectiveness of immunotherapy. Researchers at Bar-Ilan University have unveiled a technology that promises to improve cancer treatment decisions based on a patient's biopsy. Funded by the Israel Cancer Association, the pioneering biological research and development measures changes in immune system cells adjacent to cancer cells, providing crucial insights into the patient's immune response and potentially enhancing the effectiveness of immunotherapy. Immunotherapy represents a targeted approach to cancer treatment, harnessing the body's own immune system to identify and eliminate cancer cells. Unlike traditional chemotherapy, which can have widespread effects on healthy cells, immunotherapy offers a more precise and targeted treatment option. The research, published in the scientific journal RNA, marks the first time that a direct measurement of the interaction between immune cells and cancer cells from a patient's biopsy has been achieved. This development opens new avenues for tailoring treatments to individual patients and improving outcomes. "Cancer cells have the ability to manipulate immune cells, evading the body's natural defenses," explains Dr. Shahar Alon, lead researcher at Bar-Ilan University's Faculty of Engineering. "By quantifying the molecular changes that occur when immune cells encounter cancer cells, we gain a deeper understanding of this complex interplay." Using advanced scanning techniques developed by Dr. Alon's research group, the team examined how immune cells express genes differently when in proximity to cancer cells. They found that specific types of immune cells exhibit distinct genetic signatures when near cancerous tissue. "The analysis revealed dozens of genes that are uniquely expressed in immune cells that interact with cancer cells," says Dr. Alon. "Notably, CD8 T immune cells, known for their ability to directly bind and eliminate cancer cells, showed a higher level of gene activation compared to CD4 T cells." This innovative approach to sequencing biopsies offers a powerful tool for identifying genes involved in the immune response to cancer. By assessing the degree of immune system activation in individual patients, clinicians can make more informed decisions about immunotherapy treatments, ultimately improving patient outcomes. Moshe Bar Haim, CEO of the Israel Cancer Association, emphasizes the global significance of this research: "Research knows no boundaries, and every breakthrough has the potential to benefit patients worldwide. This new understanding of the immune system's response to cancer cells holds promise for more effective treatments and higher recovery rates." Led by student researchers Michal Danino and Tal Goldberg, under the guidance of Dr. Alon and Prof. Gonen Singer, this study received funding from the Israel Cancer Association, the Israel National Science Foundation, and the Sheba/Bar-Ilan grant.

免疫疗法

2024-05-02

·PRNewswire

SwiftDuct Presents Positive Clinical Study Results of SwiftGlide For ERCP Procedures at ESGE Days 2024

SwiftDuct's first clinical study, which was conducted at Galilee Medical Center, demonstrates that the company's electrochemical navigation method has the potential to improve ERCP procedures and outcomes, marking an important milestone towards Fluoroscopy-Free ERCP cannulation.ERCP is a widely used procedure to diagnose and treat issues in the bile or pancreatic ducts. SAKHNIN, Israel, May 2, 2024 /PRNewswire/ -- In a poster presentation at the 2024 annual meeting of the European Society of Gastrointestinal Endoscopy, ESGE Days 2024, SwiftDuct announced the positive findings of the first clinical trial of SwiftGlide™, the company's electrochemical navigation system for ERCP procedures. The study showed that SwiftGlide™ was successful in differentiating between bile and pancreatic/mixed juices as the basis to providing selective and safe biliary cannulation during ERCP procedures. Continue Reading SwiftDuct study’s principal investigator Tawfik Khoury, M.D. and SwiftDuct CEO Samer Abboud at ESGE Days 2024 where the company’s trial data was presented for the first time. The poster, titled Electrochemical in-situ intraoperative testing during ERCP for safer cannulation: A Novel Approach Using Multi-Pole Electrodes and Electrochemical Impedance Spectroscopy, was presented by the study's principal investigator Dr. Tawfik Khoury, Senior Consultant Gastroenterologist at Galilee Medical Center & EMMS Nazareth Hospital and Assistant Professor at Bar-Ilan University. The data from 14 patients, collected at Galilee Medical Center, in Nahariya, Israel, demonstrated that SwiftGlide™'s multi-pole sensors were able to differentiate between bile and pancreatic/mixed juices. Dr. Khoury said, "We are thrilled with these initial clinical findings, though, of course, this is just the beginning and further studies should be conducted." Dr. Wisam Sbeit, Head Manager of the Gastroenterology Department at Galilee Medical Center said, "SwiftDuct has in its hands a promising new technology that has the potential to enable endoscopists to quickly and efficiently conduct an ERCP procedure with selective biliary cannulation, improve patient outcomes and reduce the occurrence of post ERCP pancreatitis, hospital stays and costs." SwiftDuct CEO Mr. Samer Abboud said, "The differentiation between bile and pancreatic/mixed juices provides the first ever opportunity for the most accurate ERCP, without, or with a minimal need for fluoroscopy. Together with Swiftome™, a superior Papillotom in development, we provide an advanced ERCP navigation kit that empowers endoscopists to reach the bile duct without inadvertent cannulation of the pancreatic duct, enabling Fluoroscopy-Free ERCP cannulation, and minimizing the rate of post-ERCP pancreatitis." About SwiftDuct SwiftDuct is developing the SwiftGlide™ with integrated sensors that "feel" the surrounding fluids while navigating through the ducts and indicating the real-time anatomical location of the wire. A "green light" is given when heading in the right direction towards the bile duct and an alert is given when going in the wrong direction to the pancreatic duct. To overcome anatomical variations and enable easier maneuverability within the ducts, SwiftDuct is also developing the Swiftome™, a superior Papillotom with exceptional distal bending flexibility. SwiftDuct is a MEDX Xelerator portfolio company, located at the incubator's Sakhnin branch in Northern Israel. For more information: Press Contact Marjie Hadad Must Have Communications On behalf of SwiftDuct +972-54-536-5220 917-790-1178 Photo - SOURCE SwiftDuct

100 项与 Bar-Ilan University 相关的药物交易

登录后查看更多信息

100 项与 Bar-Ilan University 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年12月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

E-260 ( FER )	肿瘤更多	临床前
CP-2 ( APP x NMDA receptor )	阿尔茨海默症更多	临床前
Compound 34(Bar Ilan University) ( AMPK )	糖尿病更多	临床前
PT-1 ( AMPK )	糖尿病更多	临床前
Pivaloyloxymethyl Butyrate ( HDACs )	肝癌更多	终止